NR3C2 and metabolic dysfunction-associated steatotic liver disease: Only a few studies have assessed the effect of spironolactone or other mineralocorticoid receptor (MR) inhibitors on lipid metabolism, and they were all conducted in populations or conditions different than NAFLD.